Study assessing safety of cobimetinib plus vemurafenib in patients with unresectable or metastatic melanoma: Real life data from the French temporary authorization for use program.

Trial Profile

Study assessing safety of cobimetinib plus vemurafenib in patients with unresectable or metastatic melanoma: Real life data from the French temporary authorization for use program.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Expanded access
  • Most Recent Events

    • 02 Dec 2016 New trial record
    • 11 Oct 2016 Results assessing safety presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top